Intersect ENT (XENT) 10-Q 5 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Document Period End Date	Sep. 30, 2019
Entity Central Index Key	0001271214
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Intersect ENT, Inc.
Entity Filer Category	Large Accelerated Filer
Trading Symbol	XENT
Entity Common Stock, Shares Outstanding		31,514,901
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	false
Document Quarterly Report	true
Document Transition Report	false
Local Phone Number	641-2100
City Area Code	650
Entity Address, Postal Zip Code	94025
Entity Address, City or Town	Menlo Park
Entity Tax Identification Number	20-0280837
Entity Address, Address Line One	1555 Adams Drive
Entity File Number	001-36545
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Sep. 30, 2019	Dec. 31, 2018		Dec. 01, 2018	[1]
Current assets:
Cash and cash equivalents		$ 10,354	$ 9,464	[1]
Short-term investments, available-for-sale		78,873	91,309	[1]
Accounts receivable, net		13,243	19,616	[1]
Inventory		16,921	11,586	[1]
Prepaid expenses and other current assets		3,809	2,695	[1]
Total current assets		123,200	134,670	[1]
Property and equipment, net		6,072	5,878	[1]
Other non-current assets		1,010	413	[1]
Total assets		130,282	140,961	[1]
Current liabilities:
Accounts payable		4,788	6,202	[1]
Accrued compensation		12,655	12,281	[1]
Other current liabilities		1,912	1,250	[1]
Total current liabilities		19,355	19,733	[1]
Other non-current liabilities		44	234	[1]
Total liabilities		19,399	19,967	[1]
Commitments and contingencies (note 9)
Stockholders' equity:
Preferred stock, $0.001 par value; Authorized shares: 10,000 at September 30, 2019 and December 31, 2018; Issued and outstanding shares: none	[1]	0	0
Common stock, $0.001 par value; Authorized shares: 150,000 at September 30, 2019 and December 31, 2018; Issued and outstanding shares: 31,510 at September 30, 2019 and 30,745 at December 31, 2018		32	31	[1]
Additional paid-in capital		333,556	308,766	[1]
Accumulated other comprehensive income (loss)		94	(41)	[1]
Accumulated deficit		(222,799)	(187,762)	[1]
Total stockholders' equity		110,883	120,994	[1]
Total liabilities and stockholders' equity		$ 130,282	$ 140,961	[1]
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	31,510,000	30,745,000
Common stock, shares outstanding	31,510,000	30,745,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenue	$ 24,056	$ 24,666	$ 77,388	$ 75,689
Cost of sales	4,876	5,202	14,567	16,242
Gross profit	19,180	19,464	62,821	59,447
Operating expenses:
Selling, general and administrative	26,429	22,760	81,247	65,281
Research and development	6,145	4,872	18,452	13,519
Total operating expenses	32,574	27,632	99,699	78,800
Loss from operations	(13,394)	(8,168)	(36,878)	(19,353)
Interest income and other, net	546	572	1,841	1,461
Net loss	(12,848)	(7,596)	(35,037)	(17,892)
Other comprehensive income:
Unrealized (loss) gain on short-term investments, net	(3)	46	135	51
Comprehensive loss	$ (12,851)	$ (7,550)	$ (34,902)	$ (17,841)
Net loss per share, basic and diluted	$ (0.41)	$ (0.25)	$ (1.12)	$ (0.59)
Weighted average common shares used to compute net loss per share, basic and diluted	31,483	30,475	31,256	30,208

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance, Value at Dec. 31, 2017	$ 117,219		$ 30	$ 282,121	$ (92)	$ (164,840)
Beginning balance, Shares at Dec. 31, 2017			29,678
Issuance of common stock and exercise of stock options, Value	4,224			4,224
Issuance of common stock and exercise of stock options, Shares			421
Stock-based compensation expense	3,138			3,138
Unrealized gain (loss) on short-term investments	(65)				(65)
Net loss	(6,136)					(6,136)
Ending balance, Value at Mar. 31, 2018	118,380		$ 30	289,483	(157)	(170,976)
Ending balance, Shares at Mar. 31, 2018			30,099
Beginning balance, Value at Dec. 31, 2017	117,219		$ 30	282,121	(92)	(164,840)
Beginning balance, Shares at Dec. 31, 2017			29,678
Unrealized gain (loss) on short-term investments	51
Net loss	(17,892)
Ending balance, Value at Sep. 30, 2018	119,807		$ 30	302,550	(41)	(182,732)
Ending balance, Shares at Sep. 30, 2018			30,529
Beginning balance, Value at Mar. 31, 2018	118,380		$ 30	289,483	(157)	(170,976)
Beginning balance, Shares at Mar. 31, 2018			30,099
Issuance of common stock and exercise of stock options, Value	4,484			4,484
Issuance of common stock and exercise of stock options, Shares			336
Stock-based compensation expense	3,605			3,605
Unrealized gain (loss) on short-term investments	70				70
Net loss	(4,160)					(4,160)
Ending balance, Value at Jun. 30, 2018	122,379		$ 30	297,572	(87)	(175,136)
Ending balance, Shares at Jun. 30, 2018			30,435
Issuance of common stock and exercise of stock options, Value	1,371			1,371
Issuance of common stock and exercise of stock options, Shares			94
Stock-based compensation expense	3,607			3,607
Unrealized gain (loss) on short-term investments	46				46
Net loss	(7,596)					(7,596)
Ending balance, Value at Sep. 30, 2018	119,807		$ 30	302,550	(41)	(182,732)
Ending balance, Shares at Sep. 30, 2018			30,529
Beginning balance, Value at Dec. 31, 2018	120,994	[1]	$ 31	308,766	(41)	(187,762)
Beginning balance, Shares at Dec. 31, 2018			30,745
Issuance of common stock and exercise of stock options, Value	4,467			4,467
Issuance of common stock and exercise of stock options, Shares			417
Stock-based compensation expense	4,014			4,014
Unrealized gain (loss) on short-term investments	77				77
Net loss	(10,805)					(10,805)
Ending balance, Value at Mar. 31, 2019	118,747		$ 31	317,247	36	(198,567)
Ending balance, Shares at Mar. 31, 2019			31,162
Beginning balance, Value at Dec. 31, 2018	120,994	[1]	$ 31	308,766	(41)	(187,762)
Beginning balance, Shares at Dec. 31, 2018			30,745
Unrealized gain (loss) on short-term investments	135
Net loss	(35,037)
Ending balance, Value at Sep. 30, 2019	110,883		$ 32	333,556	94	(222,799)
Ending balance, Shares at Sep. 30, 2019			31,510
Beginning balance, Value at Mar. 31, 2019	118,747		$ 31	317,247	36	(198,567)
Beginning balance, Shares at Mar. 31, 2019			31,162
Issuance of common stock and exercise of stock options, Value	4,964			4,964
Issuance of common stock and exercise of stock options, Shares			307
Stock-based compensation expense	5,680			5,680
Unrealized gain (loss) on short-term investments	61				61
Net loss	(11,384)					(11,384)
Ending balance, Value at Jun. 30, 2019	118,068		$ 31	327,891	97	(209,951)
Ending balance, Shares at Jun. 30, 2019			31,469
Issuance of common stock and exercise of stock options, Value	408		$ 1	407
Issuance of common stock and exercise of stock options, Shares			41
Stock-based compensation expense	5,258			5,258
Unrealized gain (loss) on short-term investments	(3)				(3)
Net loss	(12,848)					(12,848)
Ending balance, Value at Sep. 30, 2019	$ 110,883		$ 32	$ 333,556	$ 94	$ (222,799)
Ending balance, Shares at Sep. 30, 2019			31,510
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019		Sep. 30, 2018
Operating activities:
Net loss	$ (35,037)		$ (17,892)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,986		1,279
Amortization of right-of-use assets	853
Stock-based compensation expense	14,615		10,350
Amortization of net investment discount	(1,050)		(546)
Changes in operating assets and liabilities:
Accounts receivable, net	6,373		2,196
Inventory	(4,997)		(2,627)
Prepaid expenses and other assets	(1,066)		(255)
Accounts payable	(771)		230
Accrued compensation	374		(948)
Other liabilities	(1,238)		(169)
Net cash used in operating activities	(19,958)		(8,382)
Investing activities:
Purchases of short-term investments	(97,863)		(96,422)
Maturities of short-term investments	111,485		85,633
Purchases of property and equipment	(2,613)		(1,242)
Net cash provided by (used in) investing activities	11,009		(12,031)
Financing activities:
Proceeds from issuance of common stock and exercise of stock options	9,839		10,728
Net cash provided by financing activities	9,839		10,728
Net increase (decrease) in cash and cash equivalents	890		(9,685)
Cash and cash equivalents:
Beginning of the period	9,464	[1]	19,837
End of the period	10,354		10,152
Non-cash investing activities:
Right-of-use asset obtained in exchange for lease obligations	117
Property and equipment included in accounts payable	370		533
Lessor funded building improvements	$ 152
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Organization

Organization	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of Business Intersect ENT, Inc. (the “Company”) is incorporated​​​​​​​ in the state of Delaware and its facilities are located in Menlo Park, California. The Company is a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. The Company’s U.S. Food and Drug Administration (“FDA”) approved products are steroid releasing implants designed to treat patients suffering from chronic sinusitis who are managed by ear, nose and throat (“ENT”) physicians. These products include the PROPEL ® ® ® ® ®

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). These condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company’s wholly-owned subsidiary Intersect ENT GmbH, which the Company established in June 2018, is the U.S. dollar. Transaction gains and losses are included in interest income and other, net, on the Company’s condensed consolidated statements of operations. The interim financial data as of September 30, 2019, is unaudited and is not necessarily indicative of the results for the full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2019 and 2018. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its revenue related allowances, common stock valuation and related stock-based compensation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant Accounting Policies There have been no significant changes to the accounting policies during the nine months ended September 30, 2019, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in its Annual Report, except as described below. Leases The Company adopted Accounting Standards Codification, or ASC, Topic 842, Leases, right-of-use The results for the three and nine months ended September 30, 2019 are presented under Topic 842. The results for the three and nine months ended September 30, 2018 and other prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting under prior lease guidance, ASC Topic 840: Leases For agreements with a term of more than twelve months, the Company determines if an agreement is a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in other current and non-current Right-of-use non-current Stock-based Compensation The Company maintains equity incentive plans to provide long-term incentives for employees, consultants and members of the board of directors. The plans allow for the issuance of non-statutory non-statutory non-employee The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options and restricted stock units. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution and has elected to account for forfeitures when they occur. The valuation model used for calculating the fair value of awards for stock-based compensation expense, except for market-based awards, is the Black-Scholes option-pricing model (the “Black-Scholes model”). For market-based awards, the Monte Carlo simulation model (the “Monte Carlo simulation”) is used. Both the Black-Scholes model and Monte Carlo simulation requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted average period of time that the awards granted are expected to be outstanding), the volatility of common stock and an assumed risk-free interest rate. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. Recent Accounting Pronouncements There have been no significant changes to the disclosures in the recent accounting pronouncements during the nine months ended September 30, 2019, as compared to the recent accounting pronouncements described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in its Annual Report.

Composition of Certain Financia

Composition of Certain Financial Statement Items	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Composition of Certain Financial Statement Items	3. Composition of Certain Financial Statement Items Accounts Receivable (in thousands): September 30, December 31, Accounts receivable $ 13,333 $ 19,696 Allowance for doubtful accounts (90 ) (80 ) $ 13,243 $ 19,616 Inventory (in thousands): September 30, December 31, Raw materials $ 2,353 $ 1,872 Work-in-process 452 368 Finished goods 14,116 9,346 $ 16,921 $ 11,586 Capitalized stock-based compensation expense of $0.9 million and $0.6 million were included in inventory as of September 30, 2019 and December 31, 2018, respectively. Revenue (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 PROPEL family of products $ 22,962 $ 23,851 $ 74,257 $ 74,102 SINUVA 1,094 815 3,131 1,587 $ 24,056 $ 24,666 $ 77,388 $ 75,689

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-term Investments	9 Months Ended
	Sep. 30, 2019
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Short-term Investments	4. Cash, Cash Equivalents and Short-term Investments The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, September 30, 2019 December 31, 2018 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Cost Gains Losses Fair Value Cost Gains Losses Fair Value Cash $ 8,856 $ — $ — $ 8,856 $ 4,168 $ — $ — $ 4,168 Money market funds 1,498 — — 1,498 2,308 — — 2,308 Corporate debt securities 50,262 73 (4 ) 50,331 45,177 5 (17 ) 45,165 Commercial paper 28,517 27 (2 ) 28,542 49,161 — (29 ) 49,132 $ 89,133 $ 100 $ (6 ) $ 89,227 $ 100,814 $ 5 $ (46 ) $ 100,773 Reported as: Cash and cash equivalents $ 10,354 $ 9,464 Short-term investments, available-for-sale 78,873 91,309 $ 89,227 $ 100,773 As of September 30, 2019 and December 31, 2018, the Company had no investments with a contractual maturity of greater than one year. Based on an evaluation of securities that have been in a loss position, the Company did not recognize any other-than-temporary impairment charges during the nine months ended September 30, 2019 and year ended December 31, 2018. The Company considered various factors which included a credit and liquidity assessment of the underlying securities and the Company’s intent and ability to hold the underlying securities until the estimated date of recovery of its amortized cost.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and short-term investments, available-for-sale. value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies​​​​​​​ in measuring fair value: Level 1 – Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data. Level 3 – Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Cash, Cash Equivalents and Short-term Investments The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, September 30, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 8,856 $ — $ — $ 8,856 $ 4,168 $ — $ — $ 4,168 Money market funds 1,498 — — 1,498 2,308 — — 2,308 Corporate debt securities — 50,331 — 50,331 — 45,165 — 45,165 Commercial paper — 28,542 — 28,542 — 49,132 — 49,132 $ 10,354 $ 78,873 $ — $ 89,227 $ 6,476 $ 94,297 $ — $ 100,773 Reported as: Cash and cash equivalents $ 10,354 $ 9,464 Short-term investments, available-for-sale 78,873 91,309 $ 89,227 $ 100,773

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	6. Leases The Company’s headquarters is leased under an operating lease agreement entered into in March 2012 and expires in May 2020 10,000 May 2020 Right-of-use September 30, Upon the adoption of Topic 842 $ 1,572 Additional warehouse operating lease 117 Less: accumulated amortization (853 ) $ 836 Operating lease liabilities (in thousands): September 30, Current portion included in other current liabilities $ 1,069 Non-current non-current — $ 1,069 Cash paid for amounts included in the measurement of lease liabilities for the nine months ended September 30, 2019 was $1.4 million and was included in net cash used in operating activities in the condensed consolidated statements of cash flows. Future minimum annual operating lease payments are as follows (in thousands): Fiscal Years Ending December 31, September 30, 2019 (remaining) $ 314 2020 782 Thereafter — Total minimum payments 1,096 Less: present value adjustment (27 ) Total $ 1,069 As of September 30, 2019, the weighted average remaining lease term was

Stock-based Compensation Expens

Stock-based Compensation Expense	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	7. Stock-based Compensation Expense 2014 Equity Incentive Plan In July 2014, the Company’s board of directors approved the 2014 Equity Incentive Plan (the “2014 Plan”). The number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year, beginning on January 1, 2015, and continuing through and including January 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. On January 1, 2019, the total number of shares of common stock reserved for issuance increased by 920,190 shares to 8,965,704 shares. A summary of the Company’s stock option activity and related information (options in thousands): Nine Months Ended Options Weighted Average Outstanding, beginning of period 3,688 $ 20.84 Granted 1,821 26.09 Exercised (545 ) 14.91 Forfeited (720 ) 25.56 Outstanding, end of period 4,244 23.05 Exercisable 2,192 20.62 As of September 30, 2019, the aggregate pre-tax pre-tax A summary of the Company’s RSU activity and related information (RSUs in thousands): Nine Months Ended RSUs Weighted Average Outstanding, beginning of period 350 $ 24.92 Awarded 542 26.16 Vested (142 ) 23.34 Forfeited (144 ) 26.93 Outstanding, end of period 606 25.92 As of September 30, 2019, the aggregate pre-tax Total stock-based compensation expense recognized is as follows (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cost of sales $ 354 $ 354 $ 836 $ 944 Selling, general and administrative 4,021 2,566 11,435 7,578 Research and development 874 687 2,344 1,828 $ 5,249 $ 3,607 $ 14,615 $ 10,350 As of September 30, 2019, the amount of unearned stock-based compensation currently estimated to be expensed through the year 2023 related to unvested employee stock-based awards was $33.2 million and the weighted average period over which the unearned stock-based compensation is expected to be recognized was 2.5 years. If there are any modifications or forfeitures of the underlying unvested securities, the Company may be required to accelerate, increase or decrease any remaining unearned stock-based compensation expense. In July 2019, the Company granted a stock option subject to both service and market-based vesting conditions to purchase shares of the Company’s common stock to its new President and CEO with an exercise price of $ . The shares subject to this option will vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price targets ( $ , $ 40 and $ , respectively) are achieved at any time during the three-year period following the date of grant. Upon the end of the three-year period following the date of grant, any remaining unvested shares will be cancelled. The grant date fair value of this option was $ million, as estimated with the Monte Carlo simulation model, using the following assumptions: expected volatility of %; expected risk-free interest rate of %; expected term of years; and expected dividend yield of percent. The fair value of this option is expected to be recognized over the service period from the date of grant. 2014 Employee Stock Purchase Plan In July 2014, the Company’s board of directors approved the 2014 Employee Stock Purchase Plan (“2014 ESPP”). A total of 496,092 shares were initially reserved for issuance under the 2014 ESPP. In June 2018, the Company’s stockholders approved the Amended and Restated 2014 ESPP, increasing the total number of shares of common stock reserved for issuance under the 2014 ESPP by 1,200,000 shares to a total of 1,696,092 shares (the “Amended and Restated 2014 ESPP”). A total of 77,355 shares were issued during the nine months ended September 30, 2019.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	8. Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and common stock equivalent shares from dilutive stock options, employee stock purchases and restricted stock units outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods. The following potentially dilutive securities outstanding have been excluded from the computations of weighted average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Common stock options 4,244 3,692 4,244 3,692 Restricted stock units 606 342 606 342 Employee stock purchase plan shares 75 102 75 102 4,925 4,136 4,925 4,136

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such amounts can be reasonably estimated. Indemnification The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers . Litigation The Company may at times be involved in litigation and other legal claims in the ordinary course of business. When appropriate in the Company’s estimation, it may record reserves in its financial statements for pending litigation and other claims. In May 2019, a purported stockholder of the Company, Avi Yaron, filed a putative class action complaint in the United States District Court for the Northern District of California, entitled Yaron v. Intersect ENT, Inc., et al., 4:19-cv-02647,

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). These condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The functional currency of the Company’s wholly-owned subsidiary Intersect ENT GmbH, which the Company established in June 2018, is the U.S. dollar. Transaction gains and losses are included in interest income and other, net, on the Company’s condensed consolidated statements of operations. The interim financial data as of September 30, 2019, is unaudited and is not necessarily indicative of the results for the full year. In the opinion of the Company’s management, the interim data includes only normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2019 and 2018. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its revenue related allowances, common stock valuation and related stock-based compensation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no significant changes to the accounting policies during the nine months ended September 30, 2019, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in its Annual Report, except as described below. Leases The Company adopted Accounting Standards Codification, or ASC, Topic 842, Leases, right-of-use The results for the three and nine months ended September 30, 2019 are presented under Topic 842. The results for the three and nine months ended September 30, 2018 and other prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting under prior lease guidance, ASC Topic 840: Leases For agreements with a term of more than twelve months, the Company determines if an agreement is a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in other current and non-current Right-of-use non-current
Stock-based Compensation	Stock-based Compensation The Company maintains equity incentive plans to provide long-term incentives for employees, consultants and members of the board of directors. The plans allow for the issuance of non-statutory non-statutory non-employee The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options and restricted stock units. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution and has elected to account for forfeitures when they occur. The valuation model used for calculating the fair value of awards for stock-based compensation expense, except for market-based awards, is the Black-Scholes option-pricing model (the “Black-Scholes model”). For market-based awards, the Monte Carlo simulation model (the “Monte Carlo simulation”) is used. Both the Black-Scholes model and Monte Carlo simulation requires the Company to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted average period of time that the awards granted are expected to be outstanding), the volatility of common stock and an assumed risk-free interest rate. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no significant changes to the disclosures in the recent accounting pronouncements during the nine months ended September 30, 2019, as compared to the recent accounting pronouncements described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in its Annual Report.

Composition of Certain Financ_2

Composition of Certain Financial Statement Items (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accounts Receivable	Accounts Receivable (in thousands): September 30, December 31, Accounts receivable $ 13,333 $ 19,696 Allowance for doubtful accounts (90 ) (80 ) $ 13,243 $ 19,616
Components of Inventory	Inventory (in thousands): September 30, December 31, Raw materials $ 2,353 $ 1,872 Work-in-process 452 368 Finished goods 14,116 9,346 $ 16,921 $ 11,586
Disaggregation of Revenue	Revenue (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 PROPEL family of products $ 22,962 $ 23,851 $ 74,257 $ 74,102 SINUVA 1,094 815 3,131 1,587 $ 24,056 $ 24,666 $ 77,388 $ 75,689

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2019
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Available-for-Sale Investments by Type of Instrument	The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, September 30, 2019 December 31, 2018 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Cost Gains Losses Fair Value Cost Gains Losses Fair Value Cash $ 8,856 $ — $ — $ 8,856 $ 4,168 $ — $ — $ 4,168 Money market funds 1,498 — — 1,498 2,308 — — 2,308 Corporate debt securities 50,262 73 (4 ) 50,331 45,177 5 (17 ) 45,165 Commercial paper 28,517 27 (2 ) 28,542 49,161 — (29 ) 49,132 $ 89,133 $ 100 $ (6 ) $ 89,227 $ 100,814 $ 5 $ (46 ) $ 100,773 Reported as: Cash and cash equivalents $ 10,354 $ 9,464 Short-term investments, available-for-sale 78,873 91,309 $ 89,227 $ 100,773

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Summary of Cash, Cash Equivalents and Available-for-Sale Investments Measured at Fair Value on Recurring Basis	The following is a summary of cash, cash equivalents and short-term investments, available-for-sale, September 30, 2019 December 31, 2018 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 8,856 $ — $ — $ 8,856 $ 4,168 $ — $ — $ 4,168 Money market funds 1,498 — — 1,498 2,308 — — 2,308 Corporate debt securities — 50,331 — 50,331 — 45,165 — 45,165 Commercial paper — 28,542 — 28,542 — 49,132 — 49,132 $ 10,354 $ 78,873 $ — $ 89,227 $ 6,476 $ 94,297 $ — $ 100,773 Reported as: Cash and cash equivalents $ 10,354 $ 9,464 Short-term investments, available-for-sale 78,873 91,309 $ 89,227 $ 100,773

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Schedule of Right of Use Asset	Right-of-use September 30, Upon the adoption of Topic 842 $ 1,572 Additional warehouse operating lease 117 Less: accumulated amortization (853 ) $ 836
Schedule of operating leases liabilities	Operating lease liabilities (in thousands): September 30, Current portion included in other current liabilities $ 1,069 Non-current non-current — $ 1,069
Schedule of Annual Operating Lease Payments	Future minimum annual operating lease payments are as follows (in thousands): Fiscal Years Ending December 31, September 30, 2019 (remaining) $ 314 2020 782 Thereafter — Total minimum payments 1,096 Less: present value adjustment (27 ) Total $ 1,069

Stock-based Compensation Expe_2

Stock-based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity and related information (options in thousands): Nine Months Ended Options Weighted Average Outstanding, beginning of period 3,688 $ 20.84 Granted 1,821 26.09 Exercised (545 ) 14.91 Forfeited (720 ) 25.56 Outstanding, end of period 4,244 23.05 Exercisable 2,192 20.62
Summary of Restricted Stock Units Activity	A summary of the Company’s RSU activity and related information (RSUs in thousands): Nine Months Ended RSUs Weighted Average Outstanding, beginning of period 350 $ 24.92 Awarded 542 26.16 Vested (142 ) 23.34 Forfeited (144 ) 26.93 Outstanding, end of period 606 25.92
Summary of Stock Based Compensation Expense	Total stock-based compensation expense recognized is as follows (in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Cost of sales $ 354 $ 354 $ 836 $ 944 Selling, general and administrative 4,021 2,566 11,435 7,578 Research and development 874 687 2,344 1,828 $ 5,249 $ 3,607 $ 14,615 $ 10,350

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following potentially dilutive securities outstanding have been excluded from the computations of weighted average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): Three Months Ended Nine Months Ended 2019 2018 2019 2018 Common stock options 4,244 3,692 4,244 3,692 Restricted stock units 606 342 606 342 Employee stock purchase plan shares 75 102 75 102 4,925 4,136 4,925 4,136

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 01, 2019	Sep. 30, 2019
Summary Of Significant Accounting Policies [Line Items]
Operating Lease, Liability		$ 1,069
Deferred rent	$ 600
Cumulative effect on retained earnings	0
Headquarters [Member]
Summary Of Significant Accounting Policies [Line Items]
Operating Lease, Right-of-Use Asset		$ 1,572
Accounting Standard Update 2018-11 [Member]
Summary Of Significant Accounting Policies [Line Items]
Operating Lease, Liability	$ 2,200

Composition of Certain Financ_3

Composition of Certain Financial Statement Items - Accounts Receivable (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Receivables [Abstract]
Accounts receivable	$ 13,333	$ 19,696
Allowance for doubtful accounts	(90)	(80)
Accounts receivable, net	$ 13,243	$ 19,616	[1]
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Composition of Certain Financ_4

Composition of Certain Financial Statement Items - Components of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 2,353	$ 1,872
Work-in-process	452	368
Finished goods	14,116	9,346
Inventory	$ 16,921	$ 11,586	[1]
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Composition of Certain Financ_5

Composition of Certain Financial Statement Items - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Capitalized stock-based compensation expense	$ 0.9	$ 0.6

Composition of Certain Financ_6

Composition of Certain Financial Statement Items - Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues	$ 24,056	$ 24,666	$ 77,388	$ 75,689
Propel Family of products [Member]
Revenues	22,962	23,851	74,257	74,102
Sinuva [Member]
Revenues	$ 1,094	$ 815	$ 3,131	$ 1,587

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-term Investments - Summary of Cash, Cash Equivalents and Available-for-Sale Investments by Type of Instrument (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018		Sep. 30, 2018	Dec. 31, 2017
Net Investment [Line Items]
Cash, cash equivalents and available-for-sale investments, Amortized Cost	$ 89,133	$ 100,814
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains	100	5
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Losses	(6)	(46)
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value	89,227	100,773
Cash, cash equivalents, Estimated Fair Value	10,354	9,464	[1]	$ 10,152	$ 19,837
Short-term investments, available-for-sale, Estimated Fair Value	78,873	91,309	[1]
Cash and cash equivalents and short-term investments, available-for-sale	89,227	100,773
Cash [Member]
Net Investment [Line Items]
Cash, cash equivalents and available-for-sale investments, Amortized Cost	8,856	4,168
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value	8,856	4,168
Money Market Funds [Member]
Net Investment [Line Items]
Cash, cash equivalents and available-for-sale investments, Amortized Cost	1,498	2,308
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value	1,498	2,308
Corporate Debt Securities [Member]
Net Investment [Line Items]
Cash, cash equivalents and available-for-sale investments, Amortized Cost	50,262	45,177
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains	73	5
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Losses	(4)	(17)
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value	50,331	45,165
Commercial Paper [Member]
Net Investment [Line Items]
Cash, cash equivalents and available-for-sale investments, Amortized Cost	28,517	49,161
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Gains	27
Cash, cash equivalents and available-for-sale investments, Gross Unrealized Losses	(2)	(29)
Cash, cash equivalents and available-for-sale investments, Estimated Fair Value	$ 28,542	$ 49,132
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cash, Cash Equivalents and Sh_4

Cash, Cash Equivalents and Short-term Investments - Additional Information (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Investments with a contractual maturity of greater than one year	$ 0	$ 0
Other-than-temporary impairment charges	$ 0	$ 0

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Cash, Cash Equivalents and Short-Term Investments Available-for-Sale, by Type of Instrument (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018		Sep. 30, 2018	Dec. 31, 2017
Net Investment Income [Line Items]
Cash and cash equivalents	$ 10,354	$ 9,464	[1]	$ 10,152	$ 19,837
Short-term investments, available-for-sale	78,873	91,309	[1]
Cash and cash equivalents and short-term investments, available-for-sale	89,227	100,773
Fair Value on Recurring Basis [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	89,227	100,773
Fair Value on Recurring Basis [Member] | Cash [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	8,856	4,168
Fair Value on Recurring Basis [Member] | Money Market Funds [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	1,498	2,308
Fair Value on Recurring Basis [Member] | Corporate Debt Securities [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	50,331	45,165
Fair Value on Recurring Basis [Member] | Commercial Paper [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	28,542	49,132
Fair Value on Recurring Basis [Member] | Level 1 [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	10,354	6,476
Fair Value on Recurring Basis [Member] | Level 1 [Member] | Cash [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	8,856	4,168
Fair Value on Recurring Basis [Member] | Level 1 [Member] | Money Market Funds [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	1,498	2,308
Fair Value on Recurring Basis [Member] | Level 2 [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	78,873	94,297
Fair Value on Recurring Basis [Member] | Level 2 [Member] | Corporate Debt Securities [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	50,331	45,165
Fair Value on Recurring Basis [Member] | Level 2 [Member] | Commercial Paper [Member]
Net Investment Income [Line Items]
Cash and cash equivalents and short-term investments, available-for-sale	$ 28,542	$ 49,132
[1]	Amounts have been derived from the December 31, 2018 audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Transfer of assets from level 1 to level 2	$ 0	$ 0
Transfer of liabilities from level 1 to level 2	0	0
Transfer of assets from level 2 to level 1	0	0
Transfer of liabilities from level 2 to level 1	$ 0	$ 0

Leases - Additional Information

Leases - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)ft²	Sep. 30, 2018USD ($)
Operating Lease, Payments | $	$ 1.4
Operating Lease, Weighted Average Remaining Lease Term	8 months 12 days
Rent expense | $	$ 1.7	$ 1.5
Warehouse [Member]
Operating lease , expiration date	May 31, 2020
Total area under operating lease agreement | ft² | ft²	10,000
Operating lease, Date	2019-03
Headquarters [Member]
Lease agreement description	This lease is for 50,400 square feet and includes a renewal provision allowing the Company to extend this lease for an additional three years at 95% of the then-current fair market rental rate.
Operating lease , expiration date	May 31, 2020
Total area under operating lease agreement | ft² | ft²	50,400

Leases - Right-of-Use asset (De

Leases - Right-of-Use asset (Detail) $ in Thousands	Sep. 30, 2019USD ($)
Less: accumulated amortization	$ (853)
Right-of-use asset net	836
Warehouse [Member]
Right-of-use asset	117
Headquarters [Member]
Right-of-use asset	$ 1,572

Leases - Operating Lease Liabil

Leases - Operating Lease Liabilities (Detail) $ in Thousands	Sep. 30, 2019USD ($)
Current portion included in other current liabilities	$ 1,069
Non-current portion included in other non-current liabilities	0
Total	$ 1,069

Leases - Operating Lease Paymen

Leases - Operating Lease Payments (Detail) $ in Thousands	Sep. 30, 2019USD ($)
2019 (remaining)	$ 314
2020	782
Thereafter	0
Total minimum payments	1,096
Less: present value adjustment	(27)
Total	$ 1,069

Stock-based Compensation Expe_3

Stock-based Compensation Expense - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jan. 01, 2019	Jul. 31, 2019	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jul. 23, 2014
Unearned stock-based compensation				$ 33.2
Weighted average period for unearned stock-based compensation to be recognized				2 years 6 months
President and CEO [Member]
Fair value of options amortization period		3 years
Options granted		427,147
Options price, granted		$ 20.44
Monte Carlo Simulation Model [Member]
Grant date fair value of options		$ 2.9
Fair value assumptions expected volatility rate		47.30%
Fair value assumptions risk free interest rate		1.90%
Fair value assumptions expected term		6 years 6 months
Fair value assumptions expected dividend rate		0.00%
Share-based Compensation Award, Tranche One [Member]
Options vesting average closing share price threshold 30-day trailing		$ 32
Share-based Compensation Award, Tranche Two [Member]
Options vesting average closing share price threshold 30-day trailing		40
Share-based Compensation Award, Tranche Three [Member]
Options vesting average closing share price threshold 30-day trailing		$ 48
Employee stock purchase plan shares [Member]
Common stock, capital shares reserved for future issuance, increase during period			1,200,000
Shares authorized for future issuance			1,696,092			496,092
Shares Issued				77,355
Common Stock Options [Member]
Aggregate intrinsic value of options outstanding and exercisable				$ 3.8
Aggregate intrinsic value of options outstanding				4.5
Aggregate intrinsic value of options exercised				$ 8.8	$ 15.2
Weighted-average remaining contractual term of options outstanding				7 years 9 months 18 days
Weighted-average remaining contractual term of options exercisable				6 years 7 months 6 days
Options granted				1,821,000
Options price, granted				$ 26.09
Restricted Stock Units (RSUs) [Member]
Aggregate intrinsic value of RSUs outstanding				$ 10.3
Weighted-average remaining contractual term of RSUs outstanding				2 years
2014 Equity Incentive Plan [Member]
Percentage of shares outstanding				3.00%
Shares reserved for issuance	8,965,704
Common stock, capital shares reserved for future issuance, increase during period	920,190

Stock-based Compensation Expe_4

Stock-based Compensation Expense - Summary of Stock Option Activity (Detail) - Common Stock Options [Member] - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2019
Class of Stock [Line Items]
Options outstanding, beginning of period | shares	3,688
Options granted | shares	1,821
Options exercised | shares	(545)
Options forfeited | shares	(720)
Options outstanding, end of period | shares	4,244
Options exercisable | shares	2,192
Options price, outstanding, beginning of period | $ / shares	$ 20.84
Options price, granted | $ / shares	26.09
Options price, exercised | $ / shares	14.91
Options price, forfeited | $ / shares	25.56
Options price, outstanding, end of period | $ / shares	23.05
Options price, exercisable | $ / shares	$ 20.62

Stock-based Compensation Expe_5

Stock-based Compensation Expense - Summary of Restricted Stock Units Activity (Detail) - Restricted stock units [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning of period | shares	350
Awarded | shares	542
Vested | shares	(142)
Forfeited | shares	(144)
Outstanding, end of period | shares	606
Outstanding, beginning of period | $ / shares	$ 24.92
Awarded | $ / shares	26.16
Vested | $ / shares	23.34
Forfeited | $ / shares	26.93
Outstanding, end of period | $ / shares	$ 25.92

Stock-based Compensation Expe_6

Stock-based Compensation Expense - Summary of Stock Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 5,249	$ 3,607	$ 14,615	$ 10,350
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	354	354	836	944
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	4,021	2,566	11,435	7,578
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 874	$ 687	$ 2,344	$ 1,828

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Potentially Dilutive Securities Outstanding Excluded from the Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,925	4,136	4,925	4,136
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,244	3,692	4,244	3,692
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	606	342	606	342
Employee stock purchase plan shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	75	102	75	102